Cyclacel Pharmaceuticals develops medicines for cancer and proliferative diseases globally. Lead product fadraciclib is in Phase 1/2 trials for solid tumors and hematological malignancies. Its also being tested with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia. Plogosertib, a polo-like kinase inhibitor program, is in Phase 1/2 trials for advanced solid tumors and hematological malignancies. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center. This collaboration evaluates the safety and efficacy of three cyclacel medicines in patients with hematological malignancies. Cyclacel was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 100.0% |
| Net Debt/EBITDA | 0.3 |